NOVAVAX INC Insider Trading for April 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NOVAVAX INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in NOVAVAX INC for April 2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 5.95 | 4,819 | 28,673 | 51,643 | |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 5.95 | 3,124 | 18,588 | 65,628 | |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 46.00 | 1,101 | 50,646 | 15,221 | |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 5.95 | 4,819 | 28,673 | 51,643 | |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 27.60 | 868 | 23,957 | 5,737 | |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 5.95 | 3,124 | 18,588 | 65,628 | |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 27.00 | 619 | 16,713 | 1,242 | |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 46.00 | 1,101 | 50,646 | 15,221 | |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 224.50 | 494 | 110,905 | 2,811 | 3.3 K to 2.8 K (-14.95 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 27.60 | 868 | 23,957 | 5,737 | |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 221.67 | 356 | 78,915 | 3,305 | 3.7 K to 3.3 K (-9.72 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 27.00 | 619 | 16,713 | 1,242 | |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 220.57 | 437 | 96,390 | 3,661 | 4.1 K to 3.7 K (-10.66 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 224.50 | 494 | 110,905 | 2,811 | 3.3 K to 2.8 K (-14.95 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 219.17 | 81 | 17,753 | 4,098 | 4.2 K to 4.1 K (-1.94 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 221.67 | 356 | 78,915 | 3,305 | 3.7 K to 3.3 K (-9.72 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 218.48 | 153 | 33,428 | 4,179 | 4.3 K to 4.2 K (-3.53 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 220.57 | 437 | 96,390 | 3,661 | 4.1 K to 3.7 K (-10.66 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 217.22 | 284 | 61,691 | 4,332 | 4.6 K to 4.3 K (-6.15 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 219.17 | 81 | 17,753 | 4,098 | 4.2 K to 4.1 K (-1.94 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 216.11 | 417 | 90,117 | 4,616 | 5 K to 4.6 K (-8.29 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 218.48 | 153 | 33,428 | 4,179 | 4.3 K to 4.2 K (-3.53 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 215.01 | 134 | 28,812 | 5,033 | 5.2 K to 5 K (-2.59 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 217.22 | 284 | 61,691 | 4,332 | 4.6 K to 4.3 K (-6.15 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 213.79 | 61 | 13,041 | 5,167 | 5.2 K to 5.2 K (-1.17 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 216.11 | 417 | 90,117 | 4,616 | 5 K to 4.6 K (-8.29 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Payment of Exercise | F | 202.09 | 2,260 | 456,723 | 5,228 | 7.5 K to 5.2 K (-30.18 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 215.01 | 134 | 28,812 | 5,033 | 5.2 K to 5 K (-2.59 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | D | 202.09 | 142 | 28,697 | 7,488 | 7.6 K to 7.5 K (-1.86 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 213.79 | 61 | 13,041 | 5,167 | 5.2 K to 5.2 K (-1.17 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 202.09 | 4,819 | 973,872 | 7,630 | 2.8 K to 7.6 K (+171.43 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Payment of Exercise | F | 202.09 | 2,260 | 456,723 | 5,228 | 7.5 K to 5.2 K (-30.18 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 206.82 | 127 | 26,266 | 2,811 | 2.9 K to 2.8 K (-4.32 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | D | 202.09 | 142 | 28,697 | 7,488 | 7.6 K to 7.5 K (-1.86 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 205.69 | 83 | 17,073 | 2,938 | 3 K to 2.9 K (-2.75 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 202.09 | 4,819 | 973,872 | 7,630 | 2.8 K to 7.6 K (+171.43 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 204.71 | 152 | 31,116 | 3,021 | 3.2 K to 3 K (-4.79 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 206.82 | 127 | 26,266 | 2,811 | 2.9 K to 2.8 K (-4.32 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 204.01 | 391 | 79,767 | 3,173 | 3.6 K to 3.2 K (-10.97 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 205.69 | 83 | 17,073 | 2,938 | 3 K to 2.9 K (-2.75 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 202.85 | 412 | 83,574 | 3,564 | 4 K to 3.6 K (-10.36 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 204.71 | 152 | 31,116 | 3,021 | 3.2 K to 3 K (-4.79 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 201.93 | 833 | 168,208 | 3,976 | 4.8 K to 4 K (-17.32 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 204.01 | 391 | 79,767 | 3,173 | 3.6 K to 3.2 K (-10.97 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 200.77 | 605 | 121,464 | 4,809 | 5.4 K to 4.8 K (-11.17 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 202.85 | 412 | 83,574 | 3,564 | 4 K to 3.6 K (-10.36 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 199.86 | 959 | 191,670 | 5,414 | 6.4 K to 5.4 K (-15.05 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 201.93 | 833 | 168,208 | 3,976 | 4.8 K to 4 K (-17.32 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 198.70 | 717 | 142,465 | 6,373 | 7.1 K to 6.4 K (-10.11 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 200.77 | 605 | 121,464 | 4,809 | 5.4 K to 4.8 K (-11.17 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 197.70 | 873 | 172,594 | 7,090 | 8 K to 7.1 K (-10.96 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 199.86 | 959 | 191,670 | 5,414 | 6.4 K to 5.4 K (-15.05 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 196.77 | 560 | 110,190 | 7,963 | 8.5 K to 8 K (-6.57 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 198.70 | 717 | 142,465 | 6,373 | 7.1 K to 6.4 K (-10.11 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 5.95 | 3,124 | 18,588 | 8,523 | 5.4 K to 8.5 K (+57.86 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 197.70 | 873 | 172,594 | 7,090 | 8 K to 7.1 K (-10.96 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 46.00 | 1,101 | 50,646 | 5,399 | 4.3 K to 5.4 K (+25.62 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 196.77 | 560 | 110,190 | 7,963 | 8.5 K to 8 K (-6.57 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 27.60 | 868 | 23,957 | 4,298 | 3.4 K to 4.3 K (+25.31 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 5.95 | 3,124 | 18,588 | 8,523 | 5.4 K to 8.5 K (+57.86 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 27.00 | 619 | 16,713 | 3,430 | 2.8 K to 3.4 K (+22.02 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 46.00 | 1,101 | 50,646 | 5,399 | 4.3 K to 5.4 K (+25.62 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 27.60 | 868 | 23,957 | 4,298 | 3.4 K to 4.3 K (+25.31 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 27.00 | 619 | 16,713 | 3,430 | 2.8 K to 3.4 K (+22.02 %) |
| Apr 07 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Option Exercise | M | 5.95 | 383 | 2,279 | 11,501 | |
| Apr 07 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Option Exercise | M | 5.95 | 2,083 | 12,394 | 62,501 | |
| Apr 07 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Option Exercise | M | 46.00 | 521 | 23,966 | 10,944 | |
| Apr 07 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Option Exercise | M | 27.60 | 417 | 11,509 | 3,758 | |
| Apr 07 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 178.03 | 191 | 34,004 | 287 | 478 to 287 (-39.96 %) |
| Apr 07 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Payment of Exercise | F | 177.29 | 179 | 31,735 | 478 | 657 to 478 (-27.25 %) |
| Apr 07 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | D | 177.29 | 13 | 2,305 | 657 | 670 to 657 (-1.94 %) |
| Apr 07 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Buy | M | 177.29 | 383 | 67,902 | 670 | 287 to 670 (+133.45 %) |
| Apr 07 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Sell | S | 190.10 | 3,021 | 574,292 | 287 | 3.3 K to 287 (-91.32 %) |
| Apr 07 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Buy | M | 5.95 | 2,083 | 12,394 | 3,308 | 1.2 K to 3.3 K (+170.04 %) |
| Apr 07 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Buy | M | 46.00 | 521 | 23,966 | 1,225 | 704 to 1.2 K (+74.01 %) |
| Apr 07 2021 | NVAX | NOVAVAX INC | Trizzino John | EVP, Chief Commerci ... | Buy | M | 27.60 | 417 | 11,509 | 704 | 287 to 704 (+145.30 %) |